Araz Marachelian

Also affiliated with Children's Hospital of Los Angeles

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “Factors influencing parents’ choice of palliative treatment goals for children with relapsed or refractory neuroblastoma: A multi‐site longitudinal survey study”.

Factors influencing parents’ choice of palliative treatment goals for children with relapsed or refractory neuroblastoma: A multi‐site longitudinal survey study

Cancer(2023)10.1002/cncr.35149

N/A

0.360DataRank · unranked

10 citations

Jesse Smith, Yiwang Zhou, Rochelle Bagatell, Justin N. Baker, Susan L. Cohn +10 more

Peripheral Blood Transcript Signatures after Internal 131I-mIBG Therapy in Relapsed and Refractory Neuroblastoma Patients Identifies Early and Late Biomarkers of Internal 131I Exposures

Radiation Research(2021)10.1667/rade-20-00173.1

N/A

0DataRank · unranked

6 citations

Tim Setzkorn, David A. Edmondson, Haley Segelke, Paul F. Wilson, Katherine K. Matthay +6 more

Phase I trial of lorlatinib in combination with topotecan/cyclophosphamide in children with ALK-driven refractory or relapsed neuroblastoma: A new approaches to neuroblastoma therapy consortium study.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.10041

N/A

0DataRank · unranked

0 citations

Yaël P. Mossé, Kimberly Kayser, Yueh‐Yun Chi, Marc Chioda, Holger Thurm +14 more

Randomized phase II trial of MIBG versus MIBG/vincristine/irinotecan versus MIBG/vorinostat for relapsed/refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy Consortium.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.10500

N/A

0DataRank · unranked

4 citations

Meaghan Granger, Susan Groshen, Denice Tsao‐Wei, Anasheh Shamirian, Scarlett Czarnecki +15 more

Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to 131I‐MIBG in patients with relapsed/refractory neuroblastoma

Pediatric Blood & Cancer(2023)10.1002/pbc.30743

N/A

0DataRank · unranked

5 citations

Ajami Gikandi, Bruce Pawel, Daniel Martínez, Meaghan Granger, Araz Marachelian +6 more

Impact of an objective scoring system on initiation of therapy in patients with International Neuroblastoma Risk Group Staging System (INRGSS) stage MS neuroblastoma: A report from the Children’s Oncology Group.

Journal of Clinical Oncology(2024)10.1200/jco.2024.42.16_suppl.10003

N/A

0DataRank · unranked

1 citations

Navin Pinto, Arlene Naranjo, Jed G. Nuchtern, Edward F. Attiyeh, Rochelle Bagatell +12 more

Clinical and biologic predictors of response to MIBG therapy: A report from the new approaches to neuroblastoma therapy (NANT) consortium.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e22003

N/A

0DataRank · unranked

0 citations

Katherine K. Matthay, Susan Groshen, Yueh‐Yun Chi, Meaghan Granger, Julie R. Park +3 more